Interventional Systems have announced that Micromate has been granted a new 510(k) clearance, allowing the commercial sale of the robotic system in the USA for percutaneous procedures using computed tomography (CT) optical navigation, such as biopsies and ablations, to diagnose and treat conditions in the chest, abdomen, and musculoskeletal structures.
This latest US Food and Drug Administration (FDA) clearance further expands the scope of Micromate, which has been available in the USA since 2021 for any percutaneous needle intervention performed under live imaging using cone-beam CT, CT fluoroscopy, or a fluoroscope. The miniature robot was also cleared for integration into third-party navigation stations.
As Pedro Costa, CEO of Interventional Systems, remarks: “This clearance is a long-awaited milestone for us, and it allows us to meet the growing demand for our system in the USA. We are already in the process of executing the first installations overseas, bringing the benefits of our robotic platform to patients in the USA. We designed Micromate for versatile use within the scope of work of any interventional radiologist or oncologist, and we expect it to help hospitals gain efficiency in an era where both demand for precision and staff shortages are pressing concerns.”
Srdjan Milosavljevic, chief technology officer of Interventional Systems, also highlights: “The clinical data reviewed by the FDA as part of our submission demonstrates that we provide high accuracy in all major anatomical regions, making procedures faster and safer. We believe that both large institutions and ambulatory centres can benefit from Micromate’s unique features, and we will make sure we will always keep cost-effectiveness in mind when building on our innovative robotic technology.”